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ABSTRACT
Cytokine activated peripheral blood mononuclear (PBMC) cells, 
sometimes called ‘Lymphokine Activated Killer (LAK)’ cells, have been 
shown to mediate tumour cell cytotoxicity in vitro but their mode of action in 
vivo is poorly understood. LAK cell therapy in humans on the whole has 
been unsuccessful with only minor success against melanomas and renal 
cell carcinomas. However the mode of tumour regression in these few 
instances is still unknown. In vitro tumour cytotoxicity by LAK cells does 
occur but LAK cells do not traffic to, accumulate around or infiltrate the site of 
tumours in vivo. Intravenous infusion of LAK cells into peripheral circulation 
causes the cells to traffic to the liver and spleen for clearance. The spleen is 
a lymphoid cell reservoir and thus interaction with T cells and monocytes 
would be common. Therefore these cellular effector cells may be causing 
tumour cell regression via an indirect route, meaning they are activated by 
secondary cytokines produced by the LAK cells. This project investigates the 
hypothesis that cytokines known to be produced by LAK cells can induce an 
anti-tumour response upon monocytes in vitro.
The aim of this project was firstly to investigate the effect of cytokines 
secreted from activated (PBMC) upon monocyte mediated tumour cell 
cytotoxicity. More specifically it was to determine the exposure time and 
concentration of mitogen, which would cause LAK cells to optimally secrete 
secondary cytokines which in turn would induce monocyte tumour cell 
cytotoxicity. Analysis of cytokine secretion allowed the dose and exposure 
time of stimulus (either IL-2 or anti-CD3 antibody) which generated the 
cytokine rich supernatants to be defined. Three cytokines were examined, in 
the supernatants, to determine whether they had any effect on monocyte 
tumour cytotoxicity, using a 48hr ^H-Uridine cytotoxicity assay. Their 
concentrations were determined using bioassays and ELISA’s. The cellular 
mechanism of monocyte tumour cytotoxicity was examined by observing 
adhesion molecule upregulation (in particular LFA-1 and Mac-1), MHC II cell 
surface density and also TNF-a secretion by the monocytes. This was 
carried out to create a model of how these secondary cytokines were 
actually destroying the tumour cells.
In conclusion, recombinant IL-2 and soluble monoclonal anti-CD3 
both induced LAK activity and cytokine secretion in normal PBMC. 
Furthermore, secondary cytokines, particularly IL-1 and IFN-y, produced by 
the IL-2 stimulated cells induced both an increased TNF-a secretion and 
tumour cytotoxicity by monocytes. These two parameters were found to be 
directly proportional to one another. These results imply that secondary 
cytokine production by IL-2 activated PBMC causes increased tumour cell 
killing by monocytes in vitro. The cytokines IL-1 and IFN-y were found to be 
important in the upregulation of monocyte cytotoxicity and the cytokine TNF- 
a was found to be important in the direct mechanism of tumour cell killing. 
The adhesion molecules examined did not appear to have a role in the 
tumour cell killing. However other cytokines, mitogens and/ or adhesion 
molecules may also be involved and further study would be required to 
determine if this were the case.
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1.1 : Cancer and the Immune System
Scientists through the ages have attempted to understand how the 
body coordinates its fight against disease, in the hope that understanding 
such processes would lead to new treatments. Much is now known about the 
cells in that fight. The immune system of man contains a wide diversity of cell 
types with differing functions and morphology. The major immune cells are 
the monocytes/ macrophages, the lymphocytes and the neutrophils (1).
Monocytes are phagocytic cells which travel around the body in the 
circulation and upon stimulation (usually with particulate materials) are able 
to pass from blood vessels into surrounding tissue, thereby changing 
morphology and becoming macrophages. Antigen is first taken up by such 
phagocytic cells, processed in a complex fashion and re-expressed on the 
surface of the cell in association with class II Major Histocompatability 
Complex (MHC) molecules. Antigen can then be recognised by the T 
lymphocytes, notably CD4+ cells.
The lymphocytes can be separated into two basic sub-populations: 
cells derived from the thymus are denoted “ T cells”. One of the main 
functions of these cells, together with those cells presenting antigen, is to 
recognise newly processed antigen and MHC and produce growth factors, 
differentiation factors and signals for antibody secretion which act upon the 
other main populations of lymphocytes , those denoted as “B cells”. “B cells” 
ere derived from stem cells in the bone marrow and their main function is to 
produce antibody against the primary antigen (2).
These growth and differentiation factors produced by T cells and other 
immunocytes were found to be proteins and named cytokines (cytokines 
also have a variety of other names; being lymphokines, monokines, 
interleukins etc.). Their structure, function and physiology have been ever 
since a major research topic, as they play a central role in the fine regulation 
of the immune system. Cytokines are proteins which act as chemical 
messengers in the body. They are produced by a wide range of cells and 
have varied effects. The response elicited by a particular cytokine may vary 
from cell to cells. Cytokines are able to deliver a number of different 
message to cells, or they can enhance a single message depending upon 
the particular cytokine, which cell it acts on and what other messages the 
cell is receiving at that time (3).
Each type of cytokine has its own particular receptor and the 
presence or absence of a receptor determines whether or not the 
corresponding cytokine can affect the cells. Once there has been binding 
between the cytokine and its receptor a signal is relayed to the nucleus of
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the cell, causing the cell to induce or repress a particular response via 
protein expression , thus changing the cells behaviour. Only very small 
concentrations of cytokines are required to produce a large response, they 
were therefore initially very hard to examine but now, with the help of 
recombinant DNA technology and genetically engineered bacteria , pure 
cytokines can be manufactured in large quantities. Scientists have identified 
several types of cytokines e.g. the interleukins, tumour necrosis factor (TNF), 
interferons and the haemopoietic growth factors (colony stimulating factors, 
CSF) etc., but other cytokines ( as yet undiscovered) may play as vital a part 
in immune regulation (4).
The first real positive result using cytokines as an anti- tumour therapy 
were observed by Mule and Rosenburg (5). IL-2 was used to activate 
splenocytes , producing lymphokine activated killer (LAK) cells, which were 
able to lyse a broad spectrum of fresh tumours in short term chromium 
release assays. Injections of LAK cells and recombinant IL-2 were able to 
mediate regression of established pulmonary metastasis from a variety of 
sarcomas , a carcinoma and a melanoma. However other types of murine 
tumour required a much higher concentration of IL-2 to cause regression 
and high doses of IL-2 were found to have a detrimental effect on the body. 
Therefore the cure , and its side effects ( capillary leak syndrome and its 
cascade effects), were as harmful to the body as the disease.
Lymphocytes were then removed from cancer patients and stimulated 
with IL-2, producing human LAK cells, which were subsequently 
reintroduced to the patient together with IL-2 (6,7). This too cause some 
tumour regression without so much of an increased cytotoxic effect but the 
therapy was not working on all or even most of the patients, thus the 
question is raised why is this so?
To summarise this:
1) IL-2 and LAK are synergistic in mice
2) Even in mice, some tumours (less immunogenic) need higher doses of IL- 
2 than others.
3) The mouse tumour model is unrealistic because of:
a)immunogenic tumours
b) very early age at the start of therapy
c) IL-2 intolerance
4) Humans are unable to tolerate equivalent IL-2 doses to mice (wt/wt) and 
therapy was less successful.
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5) Human evidence is that the vast proportion of LAK cells do not traffic to 
tumours: their mode of action may therefore be secondary to their effects on 
the host immune system.
In vitro it was known that the LAK cells were capable of mediating a 
cytotoxic effect but was their a secondary cytotoxic tumour effect due to LAK 
cell cytokine secretion upon other cells of the immune system? If secondary 
cytokine are required in tumour cell killing what is their optimal non harmful 
concentration and is a synergy between cytokines needed?
The aim of this project was to investigate the ability of LAK products to 
stimulate cells of the immune system to kill tumour cells. The cytotoxic cells 
observed for stimulation by activated PBMC supernatants in this study , were 
peripheral blood monocytes because they had been shown by Ruco to be 
tumour cytotoxic under certain stimulation.
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1.2 Cytokines
LAK cells produce a wide variety of cytokines. Three were chosen for 
this study which were in our opinion, on examining the current literature, the 
most likely to effect monocytic stimulatory capabilities. These cytokines were 
IL-1, TNF-a, and IFN-y:
1.2.1 : lnterleukin-1
Interleukin 1 (IL-1) is a highly pleiotropic cytokine released primarily 
from activated monocytes and macrophages. It was first identified in 1972 
when it was observed that phytohaemagglutinin (PHA) or 
lipopolysaccharide (LPS) stimulated the release of some factors by adherent 
cells in culture and that supernatants from such cultured cells, in 
combination with PHA, could stimulate thymocyte proliferation (8). Initially 
named “Lymphocyte Activating Factor” (LAF), IL-1 is called by many other 
names which describe the proteins different reported activities. Two forms 
have been isolated : IL-1 a and IL-1 . Both polypeptides , of approximate 
Mf17kD, occur naturally in human, pig, rabbit and mouse exhibit a high
degree of inter-species homology (for example 62% homology between 
human and mouse IL-1 a (9)).
IL-1 a and IL-1 B represent the products of two distinct genes and is 
initially synthesised as 30-32kD propeptides of 270 and 269 amino acids 
respectively. Mature forms of IL-1 a and IL-1 b are represented by C-terminal 
cleavage products of 159 and 153 amino acids respectively. Both IL-1 
precursors lack the hydrophobic signal peptide thought to be required for 
extracellular transport of proteins manufactured within the cell (10). 
Biochemical data suggest the existence of a membrane bound form of IL-1
(11). However, immunochemical data indicated that IL-1 is only found 
associated with the cytoplasmic ground substance of the activated monocyte
(12). The mechanism of IL-1 secretion is unknown. IL-1 a and IL-1 (3 exert 
their effects through a specific 80-82kD receptor (12). The receptor has been 
found to have near identical affinity to each form of IL-1, therefore both IL-1 
proteins and their IL-1 precursors all compete equally for receptor binding
(13).
A number of cell types have been shown to produce IL-1 , including 
monocyte and macrophage cell lines, Langerhans cells, natural killer cells 
(NK), B cell lines, endothelial cells etc. (9).
Some reported IL-1 activities include:
1) Induction of chemotaxis in polymorphonuclear cells (PMN)
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and macrophages.
2) Induction of endothelial cell proliferation.
3) Pro-coagulant activity.
4) Enhancement of Type IV collagen production by epidermal 
cells.
5) Induction of osteoblast proliferation
6) Stimulation of bone resorption by osteoclasts.
7) Modulation of reparative functions following tissue injury.
Perhaps the most important effects of IL-1 are those related to
immune function. Some examples include (14):
1) Induction of cytokine release by T cells.
2) Co-stimulation of B cell differentiation and proliferation.
3) Augmentation of NK mediated cytotoxicity.
4) Induction of chemotaxis, degranulation and release of 
neutrophils from the bone marrow.
5) Induction of prostaglandin release, chemotaxis and tumour 
cell lysis by macrophages.
6) Secretion of acute phase proteins by hepatocytes.
7) Induction of fever.
It has also been shown that IL-1 stimulates the release of factors 
associated with the growth and differentiation of cell associated with myeloid 
and lymphoid cell lineage’s in vitro . For example, IL-1 may induce the 
production of Granulocyte colony stimulating factor (G-CSF) and 
macrophage colony stimulating factor (M-CSF) by human bone marrow 
stromal cells (15).
T cell activation with IL-1 has produced some controversial results. In 
1985 IL-1 was observed to produce an accessory signal in the activation of T 
cells. Furthermore evidence from studies using tumour cell lines suggests 
that IL-1 may induce or up regulate factors required for T cell activation and 
proliferation ( e.g. IL-2, IL-2 receptor). However, other evidence suggests IL- 
1 is not required, but rather serves to enhance the stimulatory function of 
accessory cell in T cell activation (16).
The activities attributed to IL-1 suggest several potential therapeutic 
applications including use as a vaccine adjuvant, as a wound healing agent 
or as a stimulator for haematopoesis in immunodeficiency. However, the role 
examined in this study is its effect upon peripheral blood monocytes in 
conjunction with tumour cell killing and whether activated PBMC may 
contribute to this.
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1.2.2 : Tumour Necrosis Factor-Alpha (TNF-al
TNF-a was discovered following the observation that the serum from 
mice injected with Bacillus Calmette Guerin (BCG) or LPS induced tumour 
necrosis in tumour bearing mice. TNF-a has also been termed Cachectin, 
because of its role in inducing a wasted or cachetic state through its 
inhibition of the enzyme lipoprotein lipase (21).
TNF-a is a 17kD polypeptide existing in trimer units and containing 
several possible glycosylation sites. Cloning data suggest human TNF-a is a 
157 amino acid polypeptide, processed from non-reducing electrophoresis 
studies shows a single 17kD band , suggesting that covalent interactions are 
not involved in multimer formation (3).
As well as the secreted form, a membrane -bound form of TNF-a 
exists which appears as a 26kD polypeptide translation product and 
includes a 9kD leader sequence. Although this leader sequence is removed 
co-translationally to yield the 17kD secreted form it apparently persists in 
membrane TNF (22). The primary source of TNFa is the activated 
macrophage whereas TNF-p (lymphotoxin-a) it is the activated B cell. TNF-a 
and TNF-|3 share identical actions including:
1) Osteoclast activation and bone resorption
2) Antiviral activity.
However in contrast to TNF-a, TNF-p is unable to induce the release 
of haematopoietic growth factor activity from endothelial cells in vitro. TNF-a 
has been shown to be the principal mediator of toxic shock syndrome . 
TNF-a apparently shares several bio-activities previously ascribed IL-1 (23) 
or colony stimulating factors from a variety of sources. TNF-a Also appears 
to work synergistically with other cytokines (24).
1.2.3 Interferon-y a(IFN-y1
The interferons (IFNs) were originally identified and characterised 
according to their ability to induce the production of RNA and protein in 
target cells. Type I or viral interferons including: IFN-a (leukocyte derived ) 
and IFN-p (Fibroblats derived), and are produced during viral or bacteria 
infection. Type II or immune interferon (IFN-y) is produced primarily by 
Natural Killer cells upon stimulation with mitogens or antigens.
In this study we examined the effect of IFN-y on the stimulation o 
monocytes to enhance tumour cell killing. In humans IFN-y is produced by 
the CD4+ and CD8+ T lymphocytes, in response to antigen stimulation; this 
can be modelled in vitro with either recombinant interleukin-2 (r.lL-2) or anti-
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CD3 antibodies. IFN-y increases the number of high affinity receptors for IgG 
(FcRI) on monocytes and macrophages. This has important effects in terms 
of removal of immune complexes, phagocytosis and antibody-dependent 
cellular cytotoxicity (ADCC). IFN-y has also been shown to activate oxidative 
metabolism in monocytes and macrophages and to be essential for 
clearance of intracellular organisms, such as Listeria, which grow in 
macrophages.
Human IFN-y is a polypeptide with a molecular weight of 35-70kD 
according to molecular sieve data and with a pi of 8.6-8.7. Cloning data 
suggest that IFN-y mRNA code for a 166 amino acid polypeptide of 17.1kD 
containing a 20 residue N terminal hydrophobic signal peptide and two 
potential glycosylation sites. Glycosylation at Asn 38 is associated with a 
lower molecular weight form (20 kD) whereas glycosylation at both Asn 38 
and Asn 100 yields a heavier form (25kD) according to SDS -PAGE 
analysis . It appears that in humans glycosylation has some effect on 
competitive binding of IFN-y to its receptors (27). The 50-70 kD species 
initially reported may represent a multimeric IFN-y (26).]
IFN-y exerts its biological effects through specific, saturable binding to 
a single class of high affinity receptors. IFN-y receptors can be found in a 
number of different types of tissues including myelomonocytic cells, 
lymphoid cells, mast cells , endothelial cells, fibroblasts, neuronal cells, and 
melanocytes. Receptors for IFN-y may vary between tissues i.e. those 
receptors present on monocytes are found to be different to those present in 
non haemopoietic tissue. Other than its antiviral activity IFN-y has various 
other activities which include (28):
1) Inhibition of cell growth in the presence of lymphotoxin 
(TNF-beta)
2) Induction of MHC class I and II expression in target tissues.
3) Priming macrophages for tumour cell killing and enhancing 
NK cytotoxicity (29,30)
4) A possible role in the induction of cytolytic activity in LAK 
and CTL cells by up regulating the p55 component of the 
IL-2 receptor.
5) Up regulation of the secretory component which is required 
for both binding and transport of secreted IgA, IgM and IgG 
Fc receptors on PMN
6) An important role in B cell differentiation and has been
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shown to induce or enhance Ig secretion in resting B 
lymphocytes
IFN-y has a number of possible clinical uses in the treatment of 
psoriatic arthritis and in the early stages of hepatitis infection. The most 
publicised uses for IFN-y have been those involving cancer treatment but the 
results of such experiments on the whole have been disappointing. For 
example, IFN-y has been tested in phase I and II clinical trials in combination 
with antibodies to metastatic colorectal carcinoma cells. The treatment is 
based on ADCC effected by the combination of IFN-y and the antibody 
CD17-1A, and has been shown to be efficacious in vitro. The poor response 
seen in patients may reflect the inadequate distribution of antibody sites of 
interest in vivo.
Therefore IFN-y is only waiting for pharmacological advances, 
towards reducing systemic toxicity and enhancing targeting methods in vivo, 
to offer a great deal to the treatment of certain clinical disorders.
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1.3 : Lymphokine Activated Killer (LAK) Cells
Tumour cells may be lysed by the host immune system in a number of 
ways. These include :
1) Natural Killer Cytotoxicity (NK). This type of killing is MHC-unrestricted, 
does not involve memory and therefore represents non-acquired innate 
immunity. Lysis is restricted to a select group of transformed cell lines: fresh 
solid tumour cells and tumour cell lines are mostly unaffected.
2) Activated Cytotoxic Lymphocytes (CTL). This involves recognition of a 
specific antigen (via MHC) and consequently represents memory-related 
immunity. On paper this may seem an excellent way to deal with the tumour 
but until the recent discovery of the MAGE antigen family which are present 
on melanomas and are recognised by autologous CTL was close to 
impossible.
3) LAK Mediated Cytotoxicity. This is another type of cytotoxicity which is 
brought about by the LAK cell (68). The LAK cell is produced by activating 
existing lymphocytes, or thymocvtes, using IL-2 or other known mitogens. 
The progenitors of LAK activity in human peripheral blood are mainly Large 
Granular Lymphocytes (LGL) with the phenotype CD3-, CD16+, NKH-1. 
However, it is now known that such variables as growth medium, stimulatory 
mitogen (and its concentration), phenotypic composition of starting cultures 
and duration of culture may influence the capacity of lymphocyte subsets to 
generate LAK activity and the phenotype of the effectors generated (69). 
Experiments have been carried out to show that this killing is distinct from 
NK killing with the use of NK resistant (Daudi) and sensitive target cells 
(K562).
Some typical properties and functions of LAK cells are (32):
1) Fresh solid tumour cells are resistant to lysis by autologous PBL 
containing NK cells, but are lysed by autologous LAK cells;
2) Fresh solid tumour cells are resistant to lysis by fresh NK containing PBL 
of normal individuals;
3) Fresh tumour cells are lysed by allogeneic LAK cells from cancer patients 
and normal individuals;
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4) Autologous T Cell Growth factor (TCGF/IL-2) stimulates LAK lytic action for 
autologous tumour;
5) Interferon has been shown to augment NK activity and to stimulate lysis of 
allogeneic but not of autologous fresh tumour;
6) LAK effectors are non-adherent and express serologically detectable T 
cell markers i.e. CD3+ but also NK cell markers e.g. CD56 and CD57;
The LAK phenomenon appears to be of particular interest because of 
the potent ability of IL-2 to both stimulate cytotoxic activity and to promote the 
expansion of the effector cell population. The early work was carried out in 
mice and it was found that these experiments required large doses of IL-2. 
The equivalent doses in humans were never reached due to toxicity but 
even reduced doses were found to be toxic, causing fever, chills, malaise, 
fluid retention and mild hepatic dysfunction. While fever, chills and malaise 
can be controlled with drugs such as acetaminophen and indomethacin, the 
problem of fluid retention is more difficult to treat (33,34). Instead of injecting 
large (and sometimes lethal) doses of cytokine into patients it was found that 
the cells which the IL-2 was stimulating in vivo could be removed from the 
body, stimulated in vitro and then replaced after activation (7).
LAK cells can be generated easily from peripheral blood 
lymphocytes, the lymphoid cells being obtained by leukapheresis or thoracic 
duct drainage. These cells can then be incubated with IL-2 and then 
reintroduced back into the body. A large amount of IL-2 is required per 
treatment/ experiment, for example a typical in vitro stimulatory dose for a 
mouse is 175,000 Units of r.lL-2/ 5x10® splenocytes(7) and further in vivo 
doses of IL-2 must be given in addition to this once the cells are 
reintroduced to the body. This is because the cells depend on the continued 
presence of IL-2 for their survival e.g. Donohue and Rosenberg, 
demonstrated that the serum half life of IL-2 was only 3 minutes (35).
Another type of activated lymphocyte can be produced by stimulation 
using the monoclonal antibody (mAb) anti-CD3 which binds to the T cell 
receptor (TCR) complex (70). The stimulated cell then has the ability to 
become cytotoxic to tumour cells and secrete various cytokines (71). This 
method of producing activated lymphocytes is useful as LAK cell therapy but 
it requires a lot of PBMC. Therefore in children in particular, due to their 
smaller blood volume, this is not a practical method. Anti-CD3 therapy 
combined with IL-2, results in a large increase in cell yield and the 
development of high LAK activity (72). LAK cell therapy has only been 
proven to work in a small proportion of individuals, showing a great intra 
species variation, in this response. Unfortunately in humans, only melanoma
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and renal cell sarcoma have demonstrated any real regression with LAK cell 
therapy (33). It has been shown that LAK cells do not accumulate at or 
infiltrate into metastatic lesions (78) and that following infusion into 
peripheral circulation they traffic through the lungs to the liver and spleen for 
clearance (34). The spleen is a lymphoid cell reservoir and thus interaction 
between LAK cells, T cells and monocytes would be common. Therefore the 
LAK cells may be causing tumour cell regression indirectly, via local 
secretion of secondary cytokines with other cells of the immune system.
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1.4 : Monocytes/Macrophages
Monocytes and macrophages are two of the main cellular phagocytes 
of the immune system, together with the neutrophil polymorphs. The blood 
monocyte is a long lived cell which is able to migrate into the tissues and 
differentiate into the tissue macrophage. Metabolically, macrophages are 
more active than monocytes, they are strongly phagocytic (due to increased 
numbers of surface receptors) and produce more types of lysosomal 
enzymes). Most monocytes and macrophages express the CD14 molecule 
on their cell membrane; however, there, can be great phenotypic ranges of 
monocytes within the body (37).
All nucleated cells express the cell surface proteins MHC I (i.e. HLA 
A,B,C etc.) and therefore can act as targets for class I restricted T cells. The 
primary role of MHC I restricted T cells is the recognition and destruction of 
virally infected, transformed or otherwise abnormal cells. Monocytes and 
macrophages also present antigen in association with MHC class II 
molecules. Macrophages are phagocytic and possess a number of 
degradative enzymes. They are particularly effective at processing and 
presenting antigen , such as bacteria and certain parasites and play a key 
role in triggering T cell mediated immunity towards intracellular parasites 
and facultative anaerobic bacteria. They accomplish this by presenting 
antigen of the infected host cells, which they have recently engulfed and 
digested, on their cell membranes in conjunction with MHC II T hese 
antigens derived from foreign bodies would thus trigger T cell recognition 
etc. Receptor mediated internalisation of immune complexes , via Fc and 
complement receptors can markedly enhance macrophage antigen 
presentation.
Over eighty five years ago Elie Metchikoff noted that mononuclear 
phagocytes from animals which were resistant to certain bacterial infections, 
had an increased ability to engulf and destroy the afore-mentioned 
microbes. In the 1970’s Evans & Alexander and Hibbs & Remington found 
that these activated macrophages ( whose morphology is different from that 
of the normal macrophage) were also capable of mediating anti-tumour 
effects (37).
Onozaki (38) stated that human peripheral blood monocytes from 
normal donors showed considerable cytotoxicity against tumour cells when 
pre-incubated in vitro for 24 hr’s with purified, human monocyte derived IL-1. 
It has also been reported that IL-1, which is produced primarily by 
monocytes (39), appears to be chemotactic for human monocytes and may
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therefore function as an auto-stimulating signal. In addition IFN-y can also 
increase the secretion of TNF-a (40, 41) and monocyte mediated cytotoxicity 
of tumour cells. (42). In fact, IL-1, IFN-y and TNF-a have all been 
demonstrated to be inducers of TNF-a mediated tumour cytotoxicity by 
monocytes (43,44). Furthermore it appears that monocytes become primed 
upon stimulation by certain cytokines and require a further stimulus (i.e. cell 
to cell contact) to bring about lysis (42,45).
Thus a complex pattern of events first reported by Ruco in 1978 (45) is 
required. The events appear to be as follows. Blood derived monocytes are 
activated with cytokines. Cytokine responsiveness, however, is labile and 
gradually lost therefore further signals are required for expression of 
cytotoxic activity, expression signals (such as adhesion molecules), from the 
tumour cells, provide the final stimulus for macrophage cytotoxicity against 
tumour cells. Another example of this complex pathway is; resting 
macrophages express low levels of MHC class II but these levels are 
markedly increased by cytokines such as IFN-y (46). At a site of possible 
inflammation or infection T-cells could secrete IFN-y which could activate 
macrophages to secrete a variety of protease’s into their local environment. 
This process could to some degree, degrade antigenic material sufficiently 
(without further processing) for presentation by other class II bearing cells. 
Thus in our experiments not only did we examine the effect the cytokines 
had on the tumouricidal properties of the monocytes but also the density of 
MHC class II (HLA-DR) present on the monocytes both pre and post cytokine 
stimulation.
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1.5 : Adhesion Molecules
Adhesive interactions between cells play a central role in the function 
of the immune system. Cell to cell contact between monocytes and tumour 
cells may enhance cytotoxicity through specific interactions between surface 
proteins an the two cell types. In the resting immune system these proteins 
must be at a base level otherwise cells expressing this same target receptor 
would be altered or destroyed by the monocyte. However, under certain 
stimuli the receptors on the monocyte (or other effector cell) may be 
increased and produce a heightened effector-target cell interaction.
Bernasconi et al (47) discovered a correlation between the leukocyte 
beta-2 integrin and tumouricidal activity of the human monocyte. The integrin 
in question is made up of two proteins, CD18 and CD11 (48). Later Jonjic 
(52) reported that the adhesion and cytotoxicity of human monocytes 
activated by IFN-y and LPS against epithelial cells involves CD18. Thus, this 
integrin appeared to be important in monocyte tumour cytotoxicity and worth 
study. There are a number of forms of this integrin, the two we chose to 
examine in our study were lymphocyte functional related antigen-1 (LFA-1) 
and Mac-1. LFA-1 is expressed on monocytes and granulocytes, as well as t 
and B lymphocytes (48,49). It is composed of two proteins CD11a and CD18 
and is thought to be induced by IFN-y (50). The LFA-1 receptor on the target 
cell is ICAM-1 or ICAM-2 (intracellular adhesion molecule) (51), both are 
members of the immunoglobulin supergene family.
Mac-1 is also a leukocyte beta-2 integrin as it is composed of the 
same CD18 protein but in contrast the second protein is CD11b. It is 
expressed on monocytes, neutrophils and NK cells. This protein is also 
known as the CR3 (Complement-3-receptor). It binds proteins containing the 
sequence Arg-Gly-Asp notably the C3 and C4 components of complement 
(in a Ca2+ dependent manner). This causes the release of oxidative 
intermediates i.e. H2 0 2  and superoxide. Expression of the protein on the cell
membrane of monocytes depends on the activation state of the cell (47).
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1.6 : Destruction of Tumour Cell by Monokines
Human peripheral blood monocytes may become tumouricidal when 
incubated with endotoxins or cytokines. After stimulation, macrophages are 
known to produce over 100 distinct molecules from the superoxide anion 
(32D) to the protein fibronectin (444kD) which are able to bring about 
diverse effects from cell division to tumour lysis (53). Several cytokines are 
secreted by activated macrophages, of which IL-1 and TNF-a have both 
been shown to produce tumour cell damage, singly (Lachman et al 1986, 
(54)) and in synergy (55). IFN-y has been reported to produce oxygen 
intermediates e.g. superoxide which are also cytotoxic to tumour cells.
Project aim
This project is aimed to examine the use of LAK cells not as cytotoxic 
effector cells, but as cytokine secreting cells which might have the ability to 
stimulate secondary effector cells of the host immune system and so thereby 
inducing fewer of the toxic effects seen with the in vivo use of IL-2. LAK cells 
may secrete different cytokine profiles depending on amount of IL-2 pre­
incubated with them and the duration of pre-incubation. The correct time and 
dose must therefore be determined to produce endogenous cytokines which 
have the desired cytotoxic effect.Then once knowing the cytokine profile of 
particular supernatants which enhanced monocyte tumour cytotoxicity, we 
could then examine in what ways this cytotoxicity was achieved. To this aim 
TNF-a levels were measured in activated monocytes to examine the 
correlation between their possible heightened concentration and tumour cell 
killing.
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INTRODUCTION
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2.1 : General Laboratory Equipment
1) Chemicals and Glassware. Unless otherwise stated all general laboratory 
chemicals and glassware were of the highest purity and quality available.
2) Heparin. The anticoagulant heparin was obtained from the hospital 
pharmacy. It was diluted to 100 lU/ml in PBS and stored at 4°C. Heparin was 
added to fresh blood, for PBMC separation, to prevent the blood from 
clotting.
3) Plastic disposables. Universals were purchased from Sterilin Ltd. 24-well 
and 96-well flat-bottomed tissue culture grade plates were purchased from 
Greiner. Syringes and needles were purchased from Becton Dickinson. All 
tissue culture flasks were purchased from Greiner and BDH.
4) Trypan Blue powder, was bought from BDH chemicals Ltd. A 1% (w/v) 
solution was prepared in PBS and solid residue was removed by filtration. 
The solution was autoclaved at 101b/ sq in. for 10mins.
5) Phosphate Buffered Saline (PBS) tablets, were bought from Sigma 
Chemicals Ltd. and added to the prescribed volume of water; the resulting 
solution was then autoclaved.
6) Bovine Serum Albumin (BSA1 was bought from Sigma and stored at 4°C.
2.2 : Tissue Culture Medium And Target Cell Lines
1) L-Glutamine. 200mM was obtained from Gibco, and stored in 1ml aliquots 
at -20 C.
2) RPMI-1640 medium was purchased from Gibco in 500ml bottles and 
stored at 4'C. Before use, 1ml of 200mM L-glutamine was added to 
100ml of medium.
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3) AIM V medium, bought from Gibco and stored in 100ml aliquots at 4°C in 
the dark.
4) K562 Cell Line was obtained from the Surgery Dept, the Western 
Infirmary Glasgow and was maintained as an adherent cell line in RPMI- 
1640 medium plus 10% foetal calf serum. It is a leukaemic cell line (Lozzio 
and Lozzio 1975).
5) SW742 Target Cell Line, a colon adenocarcinoma cell line (Leibovitz et al 
1976) was a generous gift from Dr. Russell Greig of Smith, Kline and 
Beecham and maintained as an adherent cell line in RPMI-1640 medium 
plus 10% foetal calf serum.
6) U937 Effector cell line, was obtained from the Surgery Dept. Western 
Infirmary Glasgow. It is a non-adherent diffuse histocytic lymphoma line, 
which expresses many monocyte-like characteristics exhibited by cells of 
histocytic origin and was maintained in DMEM (Gibco) plus 10% foetal calf 
serum.
7) DI0(N41M cell line obtained from Dr SJ Hopkins, Rheumatic Disease 
Centre, Hope Hospital, Salford M6 8HD, UK
8) Trypsin/EDTA was purchased from Gibco, diluted to 0.25% (v/v) in PBS 
and stored at 4 C.
9) EDTA was purchased from BDH at 2.5%(v/v) and made to 0.02% (w/v) in 
PBS, autoclaved at 10lb/sq in. for 10min and stored at 4°C.
2.3 : Radioactivity and Separation Medium
1) 51chromium was obtained from Amersham International Ltd as a stock 
solution of sodium chromate with an activity of 185MBq in 1ml. This was 
diluted to a volume of 5ml i.e. 37MBq/ml. lOOul of this solution was then used 
to label the target cells for a LAK cytotoxicity assay.
2) SH-Llrjdme was purchased from Amersham International Ltd. with an 
activity of 185MBq in 1ml. This was diluted to a volume of 5ml i.e. 37MBq/ml.
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lOOul of this solution was then used to label the target cells for a monocyte 
cytotoxicity assay.
3) Scintillation Fluid was obtained from Packard
4) Lymphocyte Separation Medium. Nycoprep was obtained from Nycomed 
Ltd. It was stored in the dark at room temperature. Its density is 1.077g/ml.
5) Monocyte Separation Medium. Nycodenz Monocytes was obtained from 
Nycomed Ltd. It was stored in the dark at room temperature. Its density is
1.068g/ml.
2.4 : Cytokines and Mitogens
1) Recombinant human Interleukin 2 was a gift from Mr. P. McCulloch Dept. 
Surgery, Western Infirmary, Glasgow.
2) Lipopolysaccharide was bought from Sigma Chemicals Ltd. in quantities 
of 1mg . This was resuspended in PBS and stored, at 4°C as 200ng/ml 
aliquots.
2.5 : Antibodies
1) Anti CD3 Antibody (SHL45.6) was a bivalent monoclonal which was 
used to produce the LAK cells, it was obtained from Dr M Clark, Dept. 
Pathology, Cambridge University.
2) Anti CD14 (UCHM1 IgGI was obtained from the Scottish Antibody 
Producing Unit in 1ml of culture supernatant, produced in a mouse. The 
antibodies Immunoglobulin Class/ Isotype was lgG2A. It was stored at 4°C
and used neat.
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3) Anti CD3 was obtained from the Scottish Antibody Producing Unit in 1 ml
of culture supernatant, produced in a mouse. The antibodies 
Immunoglobulin Class/ Isotype was IgG i. It was stored at 4°C and used
neat.
41Anti CD19 was obtained from the Scottish Antibody Producing Unit in 1 ml 
of culture supernatant, produced in a mouse. The antibodies 
Immunoglobulin Class/ Isotype was IgG i. It was stored at 4°C and used
neat.
51FITC anti -mouse IgG was raised in sheep. The IgG fraction of sheep anti­
mouse IgG is purified by treatment of the antiserum with n-octanoic acid 
followed by ion exchange chromatography. The immunoglobulin is 
conjugated to FITC and the conjugate is separated from unreacted FITC by 
gel filtration. It was obtained from the Scottish Antibody Producing Unit with 
a protein content of 9.8mg/ml. It was stored at 4°C and used neat.
6) NKH-1 was obtained from Dako in a 2ml aliquot of culture supernatant 
produced in a mouse. Its Isotype was lgG1. It was stored at 4°C and used 
neat.
7) LFA-1 . antiCDI 1a was produced from clone B-B15 , a mouse hybridoma 
of spleen cells from BALB/c mice and the mouse myeloma cell line 
X63/AG.8653, and obtained from Serotec in a volume of 2ml of purified 
Ascites.The antibodies isotype is IgG i. It was stored at 4°C and used as
recommended at 10ul per test.
81 Mac-1 , antiCDI 1b was produced from clone 44 , a mouse hybridoma and 
obtained from Serotec in a volume of 2ml of purified Ascites.The antibodies 
isotype is IgG i. It was stored at 4°C and used as recommended at 10ul per
test, (approximate Isotype concentration is 50ug/ml , determind by radial 
immunodiffuusion.
91 Anti MHCII DA6.231 was obtained from Keith Guy, Dept Immunology, 
University of Strathclyde. It was stored at 4°C and used for flow cytometry at 
the recommended concentration of a 1:10 dilution of stock.
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10) Anti-TNF-a antiserum. 1x104 neutralising units /ml of ascites was a gift 
from Dr. R Rees and used in his laboratory at concentrations quoted.
11) Anti-Interferon (gamma) antiserum. 1x10^ neutralising units/ml of 
ascites was a gift from Dr. R Rees and used in his laboratory at 
concentrations quoted.
12) Anti-Interleukin 1 antiserum. 1x1 (^neutralising units /ml of ascites was a 
gift from Dr. R Rees and used in his Laboratory at concentrations quoted.
2.6 : Hardware
1) Flow cytometer was available within the Surgery Dept, from Coulter 
Electronics Ltd.
2.7 : List of suppliers names and addresses
Amersham International Ltd.
UK Sales Office, Lincoln Place, Green End, Aylesbury,
Bucks. HP20 2TP
Becton Dickinson Ltd.
Between Towns Road, Cowley, Oxford. 0X4 3LY 
Biological Industries Ltd.
56 Telford Road, Cumbernauld, Glasgow G67 2AX 
Boehringer Ingelheim
Boehringer Ingelheim, Bender and Co., Vienna, Austria 
British Biotechnology Ltd.
Brook House, Waltington Road, Cowley, Oxford 0X4 5LY 
DAKO Ltd.
16 Manor Courtyard, Hughenden Ave, High Wycombe, Bucks HP31 5RE
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ECACC
PHLS Centre for applied Microbiology and Research, Porton Down, 
Salisbury, SP4 OJG
Gibco Ltd.
P.O. Box, Washington Rd., Abbotsinch Industrial Estate,
Paisley, PA3 4EP
Imperial Cancer Research Fund Laboratories 
P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX
Nycomed Ltd.
Nycomed House, Lampton Rd., Hounslow, Middlesex, TW3 4EE 
Mr P. McCulloch
Dept of Surgery, Western Infirmary, Byres Road, Glasgow, Scotland 
Miltenyi Biotec
1250 Oakmead Park, Suite 210, Sunnyvale, CA 94088-3599 USA 
Dr. R.C. Rees
Dept. Clinical and Experimental Microbiology, The Medical School, 
Royal Hallamshire Hospital, Sheffield.
Scottish Antibody Production Unit (SAPU)
Law Hospital, Carluke, Lanarkshire, Scotland. ML8 5ES
Serotec
22 Bankside, Station Approach, Kidlington,
Oxford. 0X5 1JE
Sigma Chemical Co. Ltd.
Fancy Road, Poole, Dorset BH17 7NH
Smith, Kline & Beecham 
Sweedlaand, PA, USA
Sterilin Ltd.
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Lampton House, Lampton Rd., Hounslow, Middlesex TW3 4EE
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3.1 : separation of Peripheral Blood Lymphocytes (PBLs) from 
Whole Blood
Fresh blood (10ml, 60ml or 120ml) was obtained from normal 
volunteer donors. For every 10ml of blood O.lml of Heparin was added. An 
equal amount of PBS was then added to the fresh blood. The resulting 
suspension was then layered onto density gradient medium in a ratio of 2:1 
(blood:lymphoprep). It was important not to allow the two layers to mix so the 
lymphoprep was added first to the 20ml centrifuge tube (universal tube). The 
tube was then tipped almost horizontal and the blood was layered on to it 
using a pipette.
The universals containing blood and lymphoprep gradient were then 
centrifuged at 400g for 30 minutes (this step separates the lymphocytes from 
other blood constituents). The centrifugation was carried out at room 
temperature and the brake on the centrifuge was switched off to allow a 
good separation. From here all the reagents and samples were kept on ice. 
The PBL layer was removed using a pasteur pipette.
To enhance the extraction process it was found that removal of the 
serum layer produced a greater yield of PBLs. The PBLs removed were 
placed into a new (pre-cooled) universal. This universal was then filled to 
1cm from the brim with cold PBS.
The universal was then placed into a cooled centrifuge (4°C) and 
spun at 1900 rpm for 15 mins, with the brake on (this spin was to remove any 
excess lymphoprep). After this centrifugation the supernatant was carefully 
poured off and the pellet was resuspended in a small amount of PBS. Once 
the pellet was resuspended, the universal was topped up with PBS.
The universal was then centrifuged at 1550 rpm for 6 mins with the 
brake on. The supernatant was then poured off again and the pellet was 
resuspended as above and the universal was topped up with PBS. The 
universal was recentrifuged at 1550 rpm for 6 mins (brake on). The 
supernatant was then poured off and the pellet was then resuspended in 1- 
4ml of growth medium (AIM-V) (56).
3 .2  : 51 Cr release Assay
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Experimental Theory
PBMC which are incubated with IL-2 or anti CD3 become activated, 
becoming LAK cells, and these activated cells can cause tumour cell lysis. 
Differing amounts of stimulation and periods of incubation time can bring 
about different levels of activation.
When a tumour target cell, which contains 51 Cr, is lysed by a LAK 
cell, it releases 51 Cr into the supernatant. This is then analysed using the 
gamma counter; i.e., only 5 lcr from lysed cells is analysed, giving a value in 
counts per minute (CPM). The wells containing target cells alone, with the 
detergent Triton-X-100 (maximum release wells), gives us a result of the 
total incorporation of 51 Cr by the target cells. The target cells in RPMI alone 
give the lowest CPM recorded, as any CPM registered is only due to 
spontaneous lysis by the target cells themselves e.g. no controlled cell 
killing (32,60). A formula to determine the %cytotoxicity generated is given 
below.
The formula used to calculate the % generated cytotoxicity is:
%Cytotoxicity = CPM Experimental-CPM spontaneous x100 
Generated CPM Max Release -CPM spontaneous
Methodology
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Target Cells
The target cells (TC) were centrifuged at 400g for 10min, then 
resuspended in 1ml of growth medium (RPMI 1640). The cells were counted, 
using a haemocytometer, and adjusted to the correct density i.e. 1x10® 
cells/ml. 2MBq of 51 Cr was then added per 1x10® cells and incubated with 
the cells at 37°C for Ihr, then washed by centrifuging three times in RPMI 
1640 at 400g for 10min. Finally, the cells were resuspended in 1ml of RPMI 
1640 plus 10% FCS, counted and adjusted according to LAK cell number 
i.e. E:T ratio. The effector to target ratio used was 25 effectors to 1 target.
Effector Cells (LAK)
After removing the LAK cells from the flask 2ml of cold RPMI was 
added to the flask to remove any adherent cells. The cells were then washed 
three times in RPMI, centrifuging each time for 10mins at 400g. The cells 
were then resuspended in 1ml of medium, counted and then diluted to give 
the correct E:T ratio (see above).
Addition of Effectors to Targets
0.1ml of the effector cells (LAK) were added to three wells of a flat- 
bottomed 96-well plate (per test); the results obtained are a mean of this 
triplicate. 0.1ml of target cells were then added to each experimental well. At 
the bottom of the plate targets were placed into two sets of six wells. To one 
of these sets was added 0.1ml of medium i.e. RPMI 1640; this set of wells 
was called the Spontaneous release wells. To the other six wells 0.1ml of 
10%(v/v) solution of Triton-X-100 (Sigma), a detergent, was added, these 
wells were known as the Maximum release wells. A mean result was also 
calculated for the Spontaneous release and the Maximum release. The 
plate was incubated for four hours at 37°C, 5%C02 •
After this time period 0.1ml of the supernatant was carefully removed 
from each well and placed into a separate gamma counter tube. The tubes 
were placed into a gamma counter and the number of counts per minute 
(CPM) emitted by each tube was recorded over a two minute period. Note 
that when the 0.1ml of supernatant was removed from the well, only liquid 
was removed i.e. all the cellular material from the assay remained on the 
bottom of the well.
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3.3 : Detection and Analysis
Flow cytometry was used to determine the purity of cell types and/or 
contaminating cell populations and observe up or down regulation of certain 
cell surface proteins.
To detect particular protein receptors present on the cell membrane a 
very sensitive instrument was required. The instrument used in our 
experiments was called an EPICS, manufactured by Coulter. This machine, 
together with mouse anti-human primary antibodies (which bind to specific 
human antigens) and goat anti-mouse secondary antibodies (which have 
the fluo rochrome FITC conjugated to their Fc region and bind to the mouse 
antibodies), made up the flow cytometric requirements to examine the 
proteins present on PBMC and monocytes.
The EPICS is a four component system consisting o f :
1) A light source, which is a laser.
2) A sample changer and optical assembly.
3) A set of associated electronics that convert light impulses into 
digital signals.
4) A printer to dump relevant information from the 
screen onto paper.
Cells to be analysed were labelled with fluorochromes and placed 
into the flow cytometer at a density of 5x105 cells/ml. The light from the laser 
is scattered by the cell. While the light is scattered in 360°, the amount of 
light scattered in the forward direction (along the axis of the light beam) is 
approximately proportional to cell size. The magnitude of this parameter, 
known as forward angle light scatter (FALS), is directly proportional to the 
size of the particle if the particle is a homogeneous sphere.
Lymphocytes (which are small cells with relatively homogenous 
nuclei and a high nucleus to cytoplasmic ratio) have low FALS, whereas 
granulocytes and monocytes, with larger more complex nuclei tend to have 
greater FALS. Also, the large angle light scatter (LALS) can be measured. 
This value coincides with the amount of light reflected by the internal 
structures of the cell, therefore granulocytes etc. have higher LALS and 
lymphocytes have lower LALS.
Fluorescence is the second event, occurring when a fluorochrome- 
bearing cell absorbs the laser light at incident wavelength and then re-emits 
the light at a longer wavelength. The emitted light is at a lower energy and is 
thus a different colour. As with scatter, the fluorescent light is emitted through
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360° but collected through an optical detector located orthogonally to the 
light beam. If several different fluorochromes are present in or on the cell, 
light of several different wavelengths is emitted at the same time and 
detected with a series of optical filters. This multicoloured emission may be 
detected by a different detector. The emission from different fluorochromes 
can then be separately quantified using a photo multiplier and a computer.
The results are divided into two categories:
i) The "mean channel" denotes the average proportion of 
fluorescence present per cell i.e. receptor density per cell. It must be noted 
that these figures are averages with 50% of the population having higher 
and 50% having lower receptor densities than this value.
ii) The "% cells" stained denotes the proportion of cells stained with at 
least one fluorochrome (appear fluorescent) with relation to the whole 
population of cells.
On average 10,000, cells were passed through the EPICS before a 
reading was taken. This was carried out so that the results were 
representative.
3.3.1 : FLOW CYTOMETRY STAINING PROTOCOL
Cells (monocytes or PBMC) obtained from whole blood using the 
protocols already described were analysed for their purity and/or the 
presence of certain protein receptors present on their surfaces by flow 
cytometry.
For each flow cytometric analysis 5x10^ cells were required. The cells 
were placed into a Iml "Eppendorf" tube and 500ul of PBS (containing 1ml 
of BSA/100ml PBS) was added. The BSA prevented FITC from sticking non- 
specifically to the lymphocytes. The tube was centrifuged for two minutes at 
600g and 4°C (this was the first wash). The supernatant was poured off 
carefully and the pellet resuspended. The 1° monoclonal antibody was then 
added ( see Table 1 for specificities and volumes used) and the tube was 
incubated at 4°C (in an ice bucket) for 15-30 minutes.
PBS was then added as above (second washing). The tube was then 
centrifuged at 600g and 4°C. The supernatant was then poured off carefully 
and discarded. The pellet was resuspended and the 2° monoclonal antibody
i.e. conjugated fluorescent marker (FITC) was then added. The tube was
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then incubated at 4°C for 15-30 minutes. Again PBS was added as before 
and the tube was recentrifuged and the supernatant was discarded. The 
pellet was then resuspended in approximately 0.2ml of PBS (1% BSA v/v) 
solution and then the sample was placed into the EPICS (65).
Note: Gloves were worn at all times.
All reagents were kept cold (4°C)i.e. cells, BSA and PBS.
When a control was used only FITC (2° monoclonal)and not 1 
monoclonal was added to the cells.
32
Table 1
Amount of neat 1° antibody added per 5x105 cells
Monoclonal Volume ul /5x105 cells Specificity
Anti CD3 100
Anti CD14 100
Anti CDI9 100
NKH-1 5
HLAI 10
HLAII 5
LFA-1 10
Mac-1 10
Binds to T  cells 
Binds to monocyte 
Binds to B cell 
Binds to NK cell CD56 
Binds to MHC class I 
Binds to MHC class II 
Binds to monocyte CDIIa 
Binds to Monocyte CD11b
Note: All the antibodies were all used neat.
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3.4 : Separation Of Peripheral Blood Monocytes
Experimental Theory
Monocytes were to be the effector cells in this system so a 
methodology was required to separate these cells from whole blood. In 
general, monocyte cell numbers are only a tenth of the PBMC population 
and thus the normal 1x10® PBMC/ml of blood translates into 1x10® 
monocytes/ml of blood. This yield is quite small and therefore large 
quantities of blood would be required to perform the cytotoxicity assays.
Thus the best separation possible was required. Three techniques were 
examined A) Separation media (59) B) Adherence (57) C) MACS (58)
Experimental Methodology
3.4.1 :Density Separation on "Nycodenz Monocytes1
Blood was collected into syringes where one volume 2.7%(w/v) EDTA 
(pH 7.4) has been added prior to collecting nine volumes of whole blood. 
Ten parts EDTA/blood were m ixed with one part 6%Dextran 500 in 0.9% 
(w/v)NaCI. The plasma layer was removed when the erythrocytes had 
settled (15-30min at 37°C). The leukocyte-rich plasma was then layered 
over Nycoprep 1.068 in 2:1 ratio. The tubes were centrifuged for 15min;
600g at room temperature. After centrifugation, the clear plasma was 
removed down to 3-4mm above the interface, and discarded. Thereafter the 
remaining plasma, together with slightly more than half the volume of 
separation fluid was collected and washed in 0.9% NaCI containing 0.13% 
EDTA and 1% heat inactivated Foetal Calf Serum (FCS) to remove 
contaminating platelets. The monocytes were washed four times in this 
solution the first centrifugation being 600g and subsequent centrifugation’s 
at 200g. The monocytes were then counted and the resuspended to a cell 
density of 1x10® cells/ml.
3.4.2 : Adherence
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50x10® PBMC (separated using Lymphoprep) were resuspended in 
20ml of RPMI 1640 plus 10% FCS. These cells were incubated for 90min in 
a 175cm tissue culture flask at 37°C. Non adherent cells were gently 
removed and the plates were washed five times in warmed PBS. After 
microscopic examination to confirm the removal of non adherent cells, 
adherent cells were recovered by incubation in 5mM EDTA for 30 min at 
37°C.
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3.5 : Monocyte Cytotoxicity Assay
Experimental Theory
Freshly-isolated monocytes were incubated with the various LAK 
supernatants to bring about their activation and hopefully increase their 
ability to cause tumour cell lysis. To quantify this a monocyte cytotoxicity 
assay must be performed. The procedure for this is similar to the 5>Cr 
release assay but here ^H-Uridine is used as the radioactive label because 
of its reduced toxicity. This must be taken into consideration bearing in mind 
that monocyte tumour cytotoxicity is a lot slower than LAK cell cytotoxicity, 
with incubation periods of 48hrs and 4hrs respectively. 51 Cr can show toxic 
effects on both the target and effector cell populations if incubated with them 
for as little as ten hours.
When a tumour target cell, which contains 3h , is lysed by a monocyte, 
it releases into the supernatant. After an incubation time of two days the 
wells containing the activated monocytes and the radioactivity labelled 
targets cells were washed to remove any radioactivity present from lysed 
tumour target cells. The living (and therefore adherent) monocytes and 
tumour target cells were then lysed using a detergent, with the lysate from 
each well being collected separately and analysed using a beta counter to 
determine how much radioactivity remains in each well i.e., only from 
intact cells is analysed, this gives a value in counts per minute (CPM). The 
target cells +Triton-X-100 (maximum release wells) gives us a result of total 
3H uptake by the target cells, as all the targets are lysed by the detergent 
releasing their into the supernatant. Control monocytes, which were 
unstimulated, were also added to the labelled targets. This produced a CPM 
result proportional to unstimulated killing, which had to be taken into 
consideration as different donors monocytes were in differing states of 
activation (prior to LAK supernatant activation) (42,45,60). The formula to 
calculate the % Generated cytotoxicity is given below:
% Generated = Control release - Experimental release X100 
cytotoxicity Control release
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This assay was also used using the U937 Cell line instead of monocytes to 
show that the effect of the supernatants was not just an artefact of a specific 
donor's monocytes.
Experimental Methodology
DAY1
Effectors
Monocytes were separated from whole blood using Nycoprep 1.068 
(see method page ). The cells were resuspended in RPMI 1640 and 10% 
FCS and counted using a haemocytometer. The cells were then adjusted to 
a density of 1x10^ monocytes/ml in RPMI medium. 100ul of this cell 
suspension was added to each well of a flat-bottomed, 96-well plate. To the 
wells containing the monocytes either 50ul of supernatant plus 50ul of 
medium or 10Oul of medium (for control) was added. The cells were 
incubated overnight at 37°C, 5% C02.
Targets
The (SW742) target cells were grown until 20-50% confluent. 1 uCi of 
tritiated (^H) uridine was then added per ml (1x106 cells) of medium and 
incubated overnight at 37°C,5% C02 ■
DAY 2 
Effectors
The effector plate containing the monocytes was turned upside down 
on a piece of tissue paper. RPMI 1640 was then used to wash all the wells of 
the plate twice, turning out the plate onto tissue paper each time. The target 
cells were then added to the plate.
Targets
The flask containing the target cells was washed twice with a little 
RPMI 1640 to remove excess isotope and dead cells. 5mls of 0.02% EDTA 
was added to the flask containing the adherent target cells and the flask 
was then incubated for 5mins. After this time the flask was gently tapped 3-4 
times and then the cells which were now non-adherent were removed and 
centrifuged with a little RPMI and 10% FCS at 1540 rpm for 6mins. 1ml of
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RPMI 1640 and 10% FCS was added to the cells which were then stained 
with Trypan blue and counted using a haemocytometer. The target cells 
concentration was then adjusted to 1 x 105 TC/ml. 200ul of this cell 
suspension was added to the previously washed plate containing the 
monocytes. The plate was then incubated for 48hrs at 37°C, 5% C02-
Controls
target cells= 100% CPM (maximum release)
monocytes+ target cells= unstimulated killing
supernatant+ monocytes+ target cells= experimental result
Note:LPS was also used on occasion to stimulate the monocytes prior to 
stimulation with the LAK supernatants to enhance supernatant activation, it 
was used at 20ng/ml. Supernatants in certain cases were also mixed, prior 
to addition to the monocytes, with anti-cytokine antisera to remove that 
specific cytokine from the supernatant
DAY 5
All of the wells of the plate were washed twice with RPMI 1640 turning 
the plate upside down each time. (If the monocyte supernatants were 
required for further analysis i.e. TNF ELISA, they were removed prior to 
plates being washed). 200ul of 10% TRITON-X-100 was then added to each 
well of the plate. The plates were placed in a 37°C incubator for 30mins. 
After this incubation the wells were aspirated 2-3 times with a pipette and 
100ul of the contents of each well was placed into a separate scintillation 
vial. The vials were then placed into a Beta scintillation counter and each 
vial was read for 3mins.
3.6 : Cytokine Quantification Methodology
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The amount of TNF-alpha and Interferon-gamma present in the individual 
supernatants was assessed using an in-house ELISA in the Dept of Clinical 
and Experimental Microbiology, Sheffield University with the permission 
and supervision of Dr C McIntyre.
The IL-1 bioassay was carried out in the Department of Medicine, the 
Royal Infirmary, Glasgow with the permission and supervision of Dr P 
Winstanley. All reagents used in the assays were provided by the afore 
mentioned laboratories.
3.6.1 : TNF-alpha ELISA
Each well of a 96 well immunoassay plate (GIBCO) was coated with 50ul 
of goat anti TNF polyclonal antibody diluted 1/500 in 0.05M carbonate buffer 
pH 9.6. The plate was incubated for 2hrs at 37°C in a humidified box. 150ul 
of TBS-BSA (2.5%) was then added to each well and the plate was 
incubated at 4 C overnight (i.e. BLOCKING STEP). The next day the plate 
was washed three times with TBS-Tween(0.1%). Standard TNF was then 
taken and diluted to the required concentrations of 100,75,50,25,10,5 and 1 
units/ml. 50ul of standard or sample was then added to each well in 
duplicate and the plate was the incubated for Ihr at 37°C. After this 
incubation the plate was washed three times in TBS-Tween (0.1%). 50ul of 
anti-TNF monoclonal antibody (101/4), diluted 1/1000 using TBS-FCS (1%), 
was added to each well and the plate was again incubated for Ihr at 37°C. 
The plate was then washed three times in TBS-Tween(0.1%). 50ul of 
biotinylated anti-mouse Ig (RPN1001), diluted 1/1000 in TBS-FCS (1%), was 
then added to each well. The plate was then incubated for Ihr at 37°C. After 
washing the plate again three times using TBS-Tween (0.1%) 50ul of 
Streptavidin-alkaline phosphatase (RPN1234) was added per well 
(RPN1234 was diluted I/500 in TBS-FCS (1%)). The plate was incubated for 
a further 30mins at 37°C and then washed three times using TBS-Tween. 
50ul of alkaline buffer was then added per well followed by 50ul of 
phosphatase substrate (4mg/ml in water). The plate was then incubated at 
37°C, in the dark, until sufficient colour had developed (approx. 20min). The 
plate was then read using a plate-reader reading at 414nm (61).
3.6.2 : Interferon-aamma ELISA
39
Each well of a 96 well immunoassay plate (GIBCO) was coated with 
50ul of goat anti IFN-y polyclonal antibody diluted 1/500 in 0.05M carbonate 
buffer pH 9.6. The plate was incubated for 2hrs at 37°C in a humidified box.
150ul of TBS-BSA (2.5%) was then added to each well and the plate was 
incubated at 4 C overnight (i.e. BLOCKING STEP). The next day the plate 
was washed three times with TBS-Tween(0.1%). Standard IFN-y was then 
taken and diluted to the required concentrations of 100,75,50,25,10,5 and 1 
units/ml. 50ul of standard or sample was then added to each well in 
duplicate and the plate was the incubated for Ihr at 37°C. After this 
incubation the plate was washed three times in TBS-Tween (0.1%). 50ul of 
anti-IFN-y monoclonal antibody (101/4), diluted I/I000 using TBS-FCS (1%), 
was added to each well and the plate was again incubated for Ihr at 37°C. 
The plate was then washed three times in TBS-Tween(0.1%). 50ul of 
biotinylated anti-mouse Ig (RPN1001), diluted 1/1000 in TBS-FCS (1%), was 
then added to each well. The plate was then incubated for Ihr at 37°C. After 
washing the plate again three times using TBS-Tween (0.1%) 50ul of 
Streptavidin-alkaline phosphatase (RPN1234) was added per well 
(RPN1234 was diluted I/500 in TBS-FCS (1%)). The plate was incubated for 
a further 30mins at 37°C and then washed three times using TBS-Tween. 
50ul of alkaline buffer was then added per well followed by 50ul of 
phosphatase substrate (4mg/ml in water). The plate was then incubated at 
37°C, in the dark, until sufficient colour had developed (approx. 20min). The 
plate was then read using a plate-reader reading at 414nm (62,63).
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3.6.3 : Bioassavs for IL-1
Experimental Theory
The bioassay used was to measure the concentration of IL-1 in the 
LAK supernatants was carried out in the laboratory of Dr P. Winstanley, The 
Dept of Medicine, The Royal Infirmary, Glasgow. The assay is based on the 
proliferative response of the D10(N4)M cell line (Source: Dr SJ Hopkins, 
Rheumatic Disease Centre, Hope Hospital, Salford M6 8HD, UK) which has 
absolute dependency on IL-1 as a growth factor. The dose-response curve 
of the D10(N4)M cells to IL-1 is made much steeper by the incorporation of 
IL-2 into the assay. The addition of a saturating IL-2 dose increases the 
specificity of the assay for IL-1 by neutralising any effect of IL-2 in the test 
sample. The amount of proliferation was determined using an MTT (3-[4,5- 
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. When MTT is 
added to viable cells they reduce the soluble tetrazolium salt to give a purple 
precipitate. This precipitate can then be solubilised and quantified using a 
spectrophotometer.
Experimental Methodology
Eight serial (1 in 3) dilution’s were made of each LAK supernatant, in 
a flat-welled micrometer plate, making a final volume of 50ul/well. The 
diluent used was basal medium (see below). Each supernatant was 
assayed in duplicate . For the controls a serial three fold dilution was made 
of the r.lL-2 (60U/ml) and a supernatant obtained from PBMC which had 
been mitogen (silica) stimulated were used as controls (thus containing 
various cytokines). D10(N4)M cells were harvested and washed once in 
basal medium. The cells were resuspended at a density of 1x105 cells/ml. 
The medium for the IL-I assay was supplemented with 60 units/ml of r.lL-2 
(Glaxo 1500U/ml). 50ul of this cell suspension was then added to each well 
and incubated at 37°C for three days.
10ul of MTT solution was then added to each well of the flat-bottomed 
microtitre plate containing 100ul of culture medium. The plate was incubated 
for 2hrs at 37°C .100ul of DMSO (Sigma) was then added to each well. The 
plates were then m ixed gently for 2-3 min on a microtitre plate shaker. The 
purple precipitate slowly dissolved, therefore the plates in general were left 
overnight at room temperature. Next day when the reduced formazan was 
fully dissolved the plates were read at 540nm(64,65).
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D10 medium : RPMI1640 +20mM HEPES 
+ 10%FCS + 1% Pen. Strep.
+ 2mM Glutamine 
+ 7.5% Na2C03
+ 3ug/ml Concanavalin A (con A)
+ 50uM 2-Mercaptoethanol
MTT : 3-[4,5-Dimethylthiazol-2-yl]-2, 
5-diphenyltetrazolium bromide; 
Sigma M2128.
dissolved at 5mg/ml in saline, then 
filtered through a 0.22um filter.
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4.1 : PBMC activation to produce LAK cells and Cytotoxicity 
assay using ®1Cr
120ml of fresh venous blood was donated by each of four young 
healthy volunteers. Nycoprep was then used to obtain peripheral blood 
mononuclear cells from the whole blood (Section 3.1). The PBMC from each 
individual donor were then separated equally into twelve culture flasks. Four 
of these flasks were labelled day 1, four labelled day 4 and four labelled 
day 8. To the four flask for each day the appropriate amount of IL-2 was 
added i.e. 0,200,1000 or 2000 Units/ml of 1x10® cells. The flasks were then 
incubated for the appropriate number of days at 37°C, 5%C02- After the
desired incubation time, the contents of the flasks were centrifuged with the 
supernatants being removed and stored, in 3ml aliquots at 37°C. The cell 
pellet was resuspended and the cells counted and adjusted to a 
concentration of 25x10® cells/ml. These cells were then used as effector 
cells in a cytotoxicity assay against target cell SW742 at a concentration of 
1x105 /ml i.e. E:T ratio was 25:1. 0.1ml of effectors were added to a 96 well 
plate and to this was added 0.1ml of target cells which had been pre­
incubated with Cr (2MBq of Cr per 1x10® target cells). The cell were 
incubated for 4hrs (SeeSection 3.2 for remainder of cytotoxicity assay 
protocol).
This whole experiment was repeated with the same four donors two 
weeks later but instead of using IL-2 to stimulate the cells the antibody anti- 
CD3 was used at concentrations of 0,1,10 and lOOng/ml (in solution). The 
supernatants were stored as before and the cells were analysed for their 
killing ability using a ®ICr release assay (See above) using both SW742 and 
K562 cell lines as target cells.
This assay was essentially carried out to make sure that the cells 
were still alive after there incubation with mitogen and thus the supernatants 
came from viable healthy cells.
The cytotoxicity results obtained showed this to be the case but can 
only be looked at in a qualitative way as the target cells did not take up the 
radioactive chromium very well and therefore the maximum release was 
quite low. Nevertheless killing was seen. (Results not shown).
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Because ninety six different supernatants were produced a easily 
recognisable code had to be derived. This code is used in the presentation 
of all of the following data. A key to the code is shown below.
EXAMPLE
W .X .Y .Z
W = Donor A ,B ,C  or D 
X = IL-2 (I) or Anti CD3 (C) stimulated
Y = Number of days the PBMC were stimulated for (1,4,8 days) 
Z = Concentration of mitogen added per ml of media i.e.
For IL-2 — 0,200,1000 or 2000 U/ml media 
For anti CD3 — 0,1,10 or 100 ng/ml of media
Therefore
AI10 = Supernatant derived from Donor A PBMC 
stimulated with zero Units/ml of IL-2 for one day.
And
DC8100 = Supernatant derived from Donor D PBMC stimulated with 
one hundred ng/ml of anti-CD3 for eight days.
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4.2 : Analysis of the LAK supernatants to determine their
cytokine profiles
The amount of three cytokines, thought to be important in the 
activation of monocytes, had to be determined in each of the LAK 
supernatants. IL-1 was determined by bioassay (detailed on page50). TNF- 
alpha and Interferon-gamma concentrations were assessed using ELISA 
(see Sections 3.6.1 and 3.6.2). Of these two methods the bioassay 
measures only active protein whereas the ELISA measures inactive as well 
but the bioassay is less quantitative than the ELISA. Ideally it would have 
been technically correct to carry out both kinds of assay, per cytokine, on 
each supernatant but time unfortunately ruled out this option.
Eventually a panel of "cytotoxic promoting" supernatants was 
ascertained from all of the initially produced supernatants. These "cytotoxic 
promoting" supernatants were used primarily in subsequent experiments to 
reduce the vastness of each assay.
Figures 1a, 1b, 1c and 1d show the data obtained from the relevant ELISA's 
and Bioassays.
Figure 1a depicts the cytokine profile data of the IL-2 produced 
supernatants from donors A and B. As can be seen from the graphs, donor B 
supernatants contain quite a low amount of IL-1 but even so it and donor A 
produce more IL-1 per incubation time at the 200 U/ml dose. Also 
predominantly the 200 Unit and also the 1000 Unit doses of IL-2 produced 
the greatest amount of Interferon gamma.
Figure 1b depicts the data for IL-2 produced supernatants from 
donors C and D. For the IL-I concentrations present in DonorC LAK 
supernatants there appears to be no real trend but, as seen in donors A and 
B, donor D shows the highest IL-I concentrations when stimulated with 200 
U/ml and the 200 unit and 1000 unit doses also produce the highest 
Interferon gamma concentrations. When looking at the TNF concentrations 
of the four donors it can be seen that donor C LAK cells secreted a lot more 
TNF-alpha than those of the other three donors with the unstimulated LAK 
cells of each day having the highest concentrations. Donor D LAK 
supernatants contain quite low levels of TNF-alpha.
Figure 1c depicts the data for anti CD3 produced supernatants from 
donors A and B. The IL-I concentrations present in donor A LAK 
supernatants were greatest per day in those supernatants produced from
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PBMC incubated with the 10ng and 100ng per ml doses of anti-CD3 and the 
10ng/ml dose for donor B produced the highest concentrations for each day 
of incubation. Looking at the presence of TNF-alpha and Interferon-gamma 
for donors A and B it can be seen that per day, predominantly, the 10ng 
dose produces the greatest response.
Figure 1d depicts the data for anti-CD3 produced supernatants from 
donors C and D. Again as for donors A and B the IL-1 concentration is 
invariably highest when the PBMC have been incubated with the 10ng/ml 
dose. The concentration of TNF-alpha in donor C supernatants is again high 
(compare donor C, anti CD3 and IL-2, induced TNF-alpha production) with 
no real trend being observed. There is also no trend in TNF-alpha secretion 
for donor D. for Interferon-gamma presence in donor C and D supernatants 
there is no trend observable.
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Figures 1a-1d: Show the concentrations of IL-1, TNF-a and IFN-y 
in each of the IL-2 or anti-CD3 activated PBMC supernatants. Filled bars 
with white dots show results of IL-1 concentrations in ngm H . Striped bars 
show results of TNF-a concentrations in Units(U)/ml. Unfilled bars with black 
dots show results of IFN-y concentrations in Units(U)/ml.
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4.3 : Which monocyte separation technique to use?
Of the methods examined to separate monocytes from peripheral 
blood (i.e. density separation medium and adherence to plastics), a number 
of factors had to be considered before choosing one methodology which 
would be used in all of the ensuing experiments.
These factors were;
i) purity ( examined using flow cytometry),
ii) yield (determined using a haemocytometer i.e.. /ml of whole 
blood),
iii) duration of method (hours)
iv) activation state (examined by clumping of the monocytes when 
observed under the microscope)
The monocytes obtained were observed taking each factor into 
consideration and the best technique was used to produce monocytes in all 
ensuing experiments. The blood used in all the experiments was kindly 
donated by members of the Surgery Department who were young and 
healthy. See Section 3.4 for methods. The cells were examined on the 
Coulter Epics, to determine purity, using antibodies specific to the different 
sub populations of white cells.
135ml of blood was obtained from a normal healthy volunteer from
this :
45ml was used to determine the proportion of monocytes present in 
this volume of fresh peripheral blood. The total number of lymphoid cells 
were 46x10®. An aliquot of these cells were stained using monoclonal 
antibodies and examined using flow cytometry. From the data presented in 
Table 2, 36.5% of cells stained positive using the anti-CD14 antibody ( mean 
of a triplicate) and Therefore the number of cells which were monocytes is 
36.5% of 46x10® which gives a figure of 16.8x10®
45ml was used in a monocyte separation using Nycodenz monocytes. 
Using this method, 5x10® cells were recovered from 45ml of blood. An 
aliquot of the cells was again examined using monoclonal antibodies and 
flow cytometry, to determine monocyte purity. The % of CD14 positive cells 
was found to be 92.1%( mean of a triplicate)(see Table 2). Therefore the 
number monocytes obtained from 45ml of blood, , was 92.1% of 5x10® 
which gives a figure of 4.6x10® monocytes
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45ml was used in a monocyte separation using the Adherence 
method. Using this method, 2 x106  cells were recovered from 45ml of blood. 
An aliquot of the cells was again examined using monoclonal antibodies 
and the flow cytometry, to determine monocyte purity. The % of CD14 
positive cells was found to be 66.1%( mean of a triplicate)(see Table 2). 
Therefore the number monocytes obtained from 45ml of blood, upon 
calculation from the data, was 66.1% of 2x10® which gives a figure of 
1.3x10® monocytes.
Therefore the Nycodenz monocyte method was the method giving the 
highest yield and purity but it was a much lengthier procedure and so I 
examined ways to improve the yield and purity of the adherence method.
4.3.1 : Adherence Method
The Adherence method of separation was faster to complete but did not 
produce a large yield of pure monocytes so the use of different brands of 
culture flasks and the %FCS in the culture media was varied to try and 
improve the adherence method outlined earlier. 110x10® PBMC were 
obtained from 100ml of fresh venous blood donated by a healthy volunteer. 
15x10® PBMC were placed into each of the BIBBY and GRENIER flasks 
together with 15ml of RPMI 1640 (containing different amounts of FCS see 
Table 2). 30x10® cells were placed into a FALCON T75 flask with 20ml of 
RPMI 1640. The cells were then incubated for 30 min see page .
As can be seen from the results shown in Table 3, the number of cells 
obtained was so low that an analysis of the monocyte purity could not be 
made. Therefore the slightly longer procedure using Nycodenz monocytes 
was adopted and used in all further experiments.
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4.3.2 : Nycodenz Monocytes
The monocytes obtained using Nycodenz monocytes method of 
separation never produced a yield of 100% monocytes, as examined by flow 
cytometry, so the contaminating populations of cells must be noted as these 
cells could be involved in cytokine induced tumour cell cytotoxicity. 
Contaminating sub-populations were stained using specific antibodies 
versus the cells and observed using flow cytometry (See Section 3.4.1).
The examination of the purity of monocytes and the contaminating 
sub populations was constantly examined and monitored throughout the 
series of experiments. A typical result is shown in Table 4. It must be noted 
that after analysis contaminating B cells (which are non-adherent) were also 
removed by carefully washing the cells i.e. the adherent monocytes 
remained in the flask.
The Nycodenz monocytes method was used to obtain all of the 
monocytes in the ensuing experiments, as this method produced the best 
yields and purity of all the methods assessed.
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Table 2
A table showing the results obtained after flow cytometry upon 
PBMC and monocytes after their relevant cell separations
Normal whole % cells No. cells Monocyte
population +ve recovered yield/(cells)
Cells 0
Cells +FITC 1.1
Cells+ A-CD14+FITC 36.5 46x10® 16.8x1 0®
Nycodenz Monocytes
Method
Cells 0.2
Cells +FITC 0.8
Cells+ A-CD14+FITC 92.1 5x106 4.6 x10®
Adherence Method
Cells 0.7
Cells +FITC 4.0
Cells+ A-CD14+FITC 66.1 2x10® 1.3x10®
Note A is used as an abbreviation for anti- when stating antibody type. 
This experiment was repeated with a different donor and similar results were 
obtained.
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Table 3
A table showing the number of cells obtained/ flask after
adherence
No. PBMC/ FlaskFlask % FCS No. monocytes
(x106 ) Brand obtain (x10®)
15 Greiner 10 0.3
15 Greiner 5 0.2
15 Bibby ...10 0.3
15 Bibby 5 0.1
30 Falcon ...10 1.2
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Table 4
A table showing examples of monocyte purity and contaminating 
subpopulations after extraction using Nycodenz monocytes.
Cells plus Cell type Range % Cells
Antibody Stained Stained
Cells None Oto 0.1
Cells + FITC Background 1.4 to 2.1
Cells + A-CD14 + FITC Monocyte 81.8 to 87.6
Cells + A-CD3 + FITC T cell 4.1 to 9.1
Cells+ A-CD19 +FITC B cell 0.9 to 10.0
Cells + NKH-1 + FITC NK cell 60.9 to 5.0
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4.4 : What effect do the LAK cell supernatants have on
monocyte tumour cytotoxicity as determined by the monocyte 
cytotoxicity assay
The LAK supernatants produced earlier were then used to try and 
enhance peripheral blood monocyte (separated from whole blood using 
Nycodenz monocytes) tumour cytotoxicity against target cells SW742, in 
vitro. This was analysed using a 48hr radioimmunoassay pre-labelling the 
SW742 cells with ^H-uridine.
Cells from the monocyte-like cell line U937 were also used as 
effector cells (instead of monocytes), for two distinct reasons. Firstly, to show 
that any effect the supernatants had upon the effector cell population was a 
genuine response which could be duplicated and not an artefact from the 
variation in monocyte donor and secondly because of the limitations of 
blood donation in the laboratory. As can be seen from graphs 2a-2d the 
monocytes in general behave in an identical manner with regards to 
cytotoxicity as do the U937 cell line.
Figure 2a is of three graphs depicting the cytotoxic effect 
supernatants A (IL-2 stimulated) had on peripheral blood monocytes and 
U937 effector cells (a monocytic cell line) upon the tumour target cells 
SW742. As can be seen from the graphs the U937 cell line is affected in a 
similar way to peripheral blood monocytes. A general trend can be seen in 
both graphs but intra assay variation is still present and the ability of the 
target cells to take up ^H-Uridine varied in each ease. Nevertheless for 
donor A the 200 and 2000 Unit doses bring about heightened cytotoxicity 
with maximal cytotoxicity being reached after about four days of incubation 
with IL-2.
With donor B, shown in figure 2b, again maximal stimulation was 
seen after four days with the 200Units of IL-2 being the optimal dose.
Figure 2c shows the cytotoxic profiles of effector cells stimulated with 
supernatants from donor C (IL-2 stimulated). For donor C there tends to be 
high basal cytotoxicity and this remains in general unaffected by addition of 
supernatants from PBMC stimulated with increasing amounts of IL-2.
Figure 2d shows optimal tumour cytotoxicity when the cells are stimulated 
with 200 Units per ml of IL-2, maximal cytotoxicity being reached at day 4.
Figure 3a and 3b depicts the cytotoxic profiles of the effector cells 
stimulated with supernatants from donor A and B respectively (anti-CD3 
stimulated). There appeared to be no real trend with the mean results being 
the same ( no matter except that the supernatants produced from 
unstimulated cells achieved a higher % generated cytotoxicity than those
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produced by stimulated supernatants. For donor C, figure 3c, there tends to 
be no stimulation caused by the anti-CD3 supernatants. Cytotoxicities 
corresponding to those determined with unstimulated PBMC supernatants 
are seen across the board. However the general level of cytotoxicity can be 
seen to be higher than those cytotoxicities observed by the other donors 
supernatants. For donor D , there again seems to be no real trend with in 
general the highest cytotoxicities seen when the supernatant’s used have 
been unstimulated with anti-CD3, figure3d. The results depicted in figure 
2a-2d and 3a-3d are all the data I was able to amass due to the time 
constraints of the project. Further experiments would need to be carried out 
to verify there statistical and reproducible content.
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Figures 2a-2d: Shows the % cytotoxicity generated by the cytokine rich 
supernatants, derived from IL-2 induced PBMC, upon peripheral blood 
monocytes, as seen using a 48hr ^H-Uridine release assay. Figures a-d 
represent the four donors, with each of the three graphs per figure 
representing the different initial time the PBMC were incubated with 
increasing concentrations of IL-2 ( x-axis) i.e. 0, 200, 1000, 2000 units 
per/ml containing 1*10® PBMC.
U = Triangle shape =The U937 cell line were used as effector cells.
M = Square shape = Monocytes were used as effector cells
The filled and unfilled shapes represent data obtained in diiferent 
separate experiments, with monocytes harvested from different donors.
—x— = The mean result of the data points per IL-2 dose
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Figure 2a
% Cytotoxicity generated by cytokine supernatants, derived
from donor A PBMC, upon peripheral blood monocytes.
IL-2 induced for one day.
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Figure 2b
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% Cytotoxicity generated by cytokine supernatants, derived
from donor B PBMC, upon peripheral blood monocytes.
IL-2 induced for one day.
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Figure 2c
T»0>
1
C4)
>.>*MJ
o
*Re**e
*
*
% Cytotoxicity generated by cytokine supernatants, derived
from donor C PBMC, upon peripheral blood monocytes.
IL-2 induced for one day.
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Figure 2d
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% Cytotoxicity generated by cytokine supernatants, derived
from donor D PBMC, upon peripheral blood monocytes.
IL-2 induced for one day.
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Figures 3a-3d: Shows the % cytotoxicity generated by the cytokine rich 
supernatants, derived from anti-CD3 antibody induced PBMC, upon 
peripheral blood monocytes, as seen using a 48hr ^H-Uridine release 
assay. Figures a-d represent the four donors, with each of the three graphs 
per figure representing the different initial time the PBMC were incubated 
with increasing concentrations of anti-CD3 antibody ( x-axis) i.e. 0, 1, 10, 
100 ng/ml containing 1*10® PBMC.
U = Triangle shape =The U937 cell line were used as effector cells.
M = Square shape = Monocytes were used as effector cells
The filled and unfilled shapes represent data obtained in diiferent 
separate experiments, with monocytes harvested from different donors.
—-x— = The mean result of the data points per anti-CD3 dose
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Figure 3a
% Cytotoxicity generated by cytokine supernatants, derived
from donor A PBMC, upon peripheral blood monocytes.
Anti-CD3 induced for one day.
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Figure 3b
% Cytotoxicity generated by cytokine supernatants, derived
from donor B PBMC, upon peripheral blood monocytes.
Anti-CD3 induced for one day.
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Figure 3c
% Cytotoxicity generated by cytokine supernatants, derived
from donor C PBMC, upon peripheral blood monocytes.
Anti-CD3 induced for one day.
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Figure 3d
% Cytotoxicity generated by cytokine supernatants, derived
from donor D PBMC, upon peripheral blood monocytes.
AntkCD3 induced for one day.
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4.5 : What role do adhesion molecules play in monocyte tumour 
cytotoxicity
The activation of the monocytes by the LAK supernatants to become 
cytotoxic against SW742 cells may require cell to cell contact between the 
activated monocyte and the tumour cell. The upregulation of two adhesion 
molecules present on the monocyte were examined to consider this. The 
adhesion molecules in question were LFA-1 and Mac-1. The presence and 
level of these adhesion molecules was examined, using mouse anti human 
antibodies against LFA-1 and Mac-1, and detected using flow cytometry (see 
Section 3.3). Monocytes were examined pre and post LAK cell supernatant 
incubation, with the incubation time being similar to that used in the 
cytotoxicity assay. The upregulation of MHC II on the cell surface of the 
monocytes was also examined, in conjunction with addition of LAK 
supernatant. This was carried out to ascertain if LAK cells were upregulating 
monocyte antigen presenting capabilities.
After this had been evaluated anti-cytokine antisera was added to the 
supernatants prior to the incubation with monocytes. The cells were then 
examined using flow cytometry to establish differences in receptor profiles 
from those previously stated. The results highlighted a possible link between 
a specific cytokine induced upregulation of adhesion molecules and the 
induction of monocyte cytotoxicity against SW742 cells. The concentration of 
IL-2 would then be known which optimally promotes LAK cells to release 
cytokine/s, in the correct concentration, to activate monocyte tumour cell 
killing in vivo.
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Figure 4 depicts the % Channel and Mean Channel, observed using 
the EPICS flow cytometer, for the monocyte cell surface adhesion molecules 
LFA-1 and Mac-1 (see Section 3.3), with and without certain of the LAK 
supernatants. As can be seen the number of each of the adhesion receptors 
upon each monocyte is directly proportional to the number of cells stained. 
There appeared to be no great change in the expression of LFA-1 on 
addition of the supernatants from that of unstimulated monocytes (MO). The 
Mac-I results showed a heightened expression per cell (% channel) and in 
the population (mean channel), when compared with the control, with those 
monocytes which had been pre-stimulated with supernatants produced from 
unstimulated LAK cells (i.e. W.X.Y.Z see section 4.1). Note that the 
supernatant B.l.1.0 experiment with LFA-1 did not work due a technical fault 
with the flow cytometer and thus no data is expressed for this. However the 
figure 4 contains this experiment for completeness, so easy comparison 
can be made between the LFA-1 and Mac-1 data.
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Figure 4
k GRAPH SHOWING LFA-1 % CHANNEL AND MEAN CHANNEL ON 
/IONOCYTES STIMULATED WITH VARIOUS LAK SUPERNATANTS
■  LFA-1 % Chan.
83 LFA-1 Mean Chan
S u p e r n a t a n t
. GRAPH SHOWING Mac-1 % CHANNEL AND MEAN CHANNEL ON 
IONOCYTES STIMULATED WITH VARIOUS LAK SUPERNATANTS
■  MAC-1 %Chan 
E3 MAC-1 Mean Chat
S u pe rn a ta n t
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Figure 5a shows the presence of MHC II, on the monocyte 
population as a whole, when stimulated with certain of the LAK 
supernatants. On the whole there is not much change in MHC II expression 
over the whole range of supernatants, with approximately 90% of monocytes 
expressing the minimumn number of MHC II molecules dectable by the flow 
cytometer. However as can be seen from the graph the number of molecules 
per cell (Mean Channel) does increase on addition of particular LAK 
supernatants.
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Figure 5b depicts the density of MHC II on monocytes with at leatst 
one receptor when incubated with certain of the LAK supernatants, with or 
without neutralising antisera. For the donor B LAK supernatants removal of 
IL-1 and IFN-y brought about a decrease in the density of MHCII per cell. 
TNF-alpha antisera when added to the LAK supernatants on the whole 
caused an increase in MHC II expression on the monocytes which were 
unstimulated, thus the antibody itself was probably causing this change i.e. 
throgh Fc binding.
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Figure 5b
Graph showing variations in MHC II mean channel 
readings on monocytes pre-incubated with LAK 
supernatants (and /o r cytokine antisera)
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4.6 : How do the activated monocytes destroy tumour cells?
The final set of experiments was designed to examine the mode of 
killing used by the monocytes to destroy the tumour target cells. Monocytes 
have several means of destroying tumour cells (see Section 1.6). but the 
primary cytokine used is TNF-alpha. Monocyte secretion of TNF-alpha was 
therefore analysed both pre and post stimulation with LAK supernatant(67).
Monocyte cytotoxicity experiments were carried out (seeSection 3.5) 
by incubating LAK cell supernatants with peripheral blood monocytes and 
then adding these activated cells to irradiated SW742 (with tritiated Uridine) 
and detecting killing in the usual way (see method). However before adding 
the Triton-X-100 the supernatants from each well were removed and stored. 
At a later date TNF ELISA's were carried out on these supernatants, to 
determine the concentration of TNF-alpha in each of the supernatants. This 
was carried out to examine a possible correlation between % cytotoxicity 
generated by the LAK supernatants and TNF-alpha secretion (a cytokine 
known to be associated with cell death; (54)). Figure 6 shows a scatter 
graph of the TNF-alpha secreted by monocytes from a single donor when 
stimulated with different LAK supernatants against the % Cytotoxicity 
generated by these monocytes upon SW742 tumour target cells. The 
statisitics using a Spearman Rank Correlation show TNF-alpha secretion is 
very significantly correlated to % cytotoxicity generated (r=0.6095, p=0.002)
Note that the important factor here is that the monocytes were washed 
before addition of the tumour target cells, so none of the TNF-alpha present 
could be from the LAK supernatants.
Next, similar experiments were carried out to those above but this 
time adding neutralising antibodies against the cytokines IL-I, Interferon- 
gamma and TNF-alpha to the LAK supernatants prior to using them to 
activate monocytes. The above procedurewas then carried out as outlined 
with in each case control wells being set up with neutralising antibodies, 
monocytes and tumourtarget cells only to determine whether the antibodies 
themselves could alter tumour cell killing or TNF-alpha secretion. From the 
normal monocyte cytotoxicity graph, (Figure 7a), the monocytes when 
stimulated with IL-2 produced LAK supernatants showed increased 
cytotoxicity on 200Unit supernatants over those unstimulated supernatants 
of the corresponding day with 1000 and 2000 Units IL-2 doses also showing 
increased cytotoxicity. When the TNF-alpha secretion was examined it could 
again be seen that incubation of the monocytes with the 200, 1000, and
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2000 Unit stimulated LAK supernatants produced a marked increase in TNF- 
alpha production.
The anti-CD3 stimulated LAK supernatants did not on the whole 
produce an equivalent amount of % generated cytotoxicity and TNF-alpha 
secretion was lower although, where it did occur, the 10 and 100 ng/ml dose 
anti-CD3 LAK supernatants did produce heightened TNF-alpha secretion to 
those unstimulated LAK supernatants of equivalent days.
When neutralising antisera for various cytokines was added to the 
supernatants prior to their incubation with the monocytes, they all brought 
about a decrease in both the % cytotoxicity generated and the amount of 
TNF-alpha secreted. The IL-1 and IFN-gamma antisera had the greatest 
effects as seen by the reduced bars on the graphs when compared with the 
whole, unmodified, supernatants, compare Figures 7b, 7c and 7d.
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Figure 6
Graph showing the correlation between TNF-alpha secreted 
by the activated monocytes and % cytotoxicity generated
100
80 -
60 -
40 -
20  -
[TNF]/U/ml
80
Figure 7a
% CYTOTOXICITY GENERATED AGAINST TUMOUR CELL TARGETS BY 
HUMAN PERIPHERAL BLOOD MONOCYTES STIMULATED 
WITH VARIOUS LAK CELL SUPERNATANTS 
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% CYTOTOXICITY GENERATED AGAINST TUMOUR CELL TARGETS BY
HUMAN PERIPHERAL BLOOD MONOCYTES STIMULATED
WITH VARIOUS LAK CELL SUPERNATANTS (IFN-GAMMA DEPLETED)
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Figure 7c
% CYTOTOXICITY GENERATED AGAINST TUMOUR CELL TARGETS 
BY HUMAN PERIPHERAL BLOOD MONOCYTES STIMULATED WITH 
VARIOUS LAK CELL SUPERNATANTS (IL-1 DEPLETED)
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CHAPTER 5
DISCUSSION
5.1 General Discussion
5.2 Recent Literature Review and Future Work
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5.1 : Discussion
It has been reported in several studies that peripheral blood 
monocytes cultured in direct contact with tumour cells are capable of 
causing tumour cytostasis and cytolysis (38,45). The addition of various 
exogenous cytokines such as interferon-gamma(30) and IL-1 (38) have 
demonstrated an enhanced effect.
In the present study endogenous cytokine was to be produced by pre­
stimulation of PBMC with IL-2 and anti-CD3 antibody. Thus only one dose 
would need to be used to give a the desired effect of monocyte tumour cell 
cytotoxicity. Of the many LAK supernatants which were originally produced, 
the 200U/ml of stimulating IL-2 for 4 days produced, the cocktail of cytokines 
which most ably induced monocyte tumour cytotoxicity in three of the four 
donors (A,B and D).
It was found that the U937Cell line behaved in a similar way to the 
donor monocytes in its ability to be stimulated by the LAK supernatants to 
become cytotoxic. Thus the effect seen was not just a one of freak 
occurrence but could be reproduced. However, small variations in 
cytotoxicity and cytokine secretion did exist between individual donors of 
both PBMC and monocytes, but as can be seen from the data the general 
trends remained the same.
On the whole, supernatants produced by stimulating PBMC with the 
anti-CD3 mAb did not stimulate monocytes to kill the tumour target cells. Any 
killing of the cells could have been due to carried over anti-CD3 present in 
the supernatants which would cause the monocytes to kill via ADCC. Donor 
C PBMC naturally secreted a high dose of TNF-alpha. This may have been 
responsible for a heightened general cytotoxicity but a lower specific 
cytotoxicity as that generated by stimulating cytokines, i.e. IFN-gamma and 
IL-I. It must also be noted that IFN-gamma and IL-I secretions are down- 
regulated by TNF-alpha in this donor. Wanidworanun et al. (73) reported that 
TNF-alpha causes monocytes to secrete IL-10 which in turn is able to 
downregulate TNF-alpha and interferon gamma secretion. Thus, levels of 
TNF-alpha produced initially in the LAK supernatants would have to be kept 
to a minimum to prevent this negative feedback mechanism. Therefore any 
monocyte cytotoxic stimulation which occurs due to the presence of these 
cytokines in donor C PBMC supernatants may be either totally or partially 
negated by the presence of TNF-alpha.
MHC class II antigen was upregulated by the LAK supernatants, 
predominantly those from the PBMC stimulated with 200U/ml of IL-2. IL-1
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and interferon-gamma were at there highest concentrations in these 
supernatants which coincides with the findings of Ezekowitz et al. 1981 (74) 
who showed an increase in MHC class-ll on monocyte cell membranes after 
stimulation with these cytokines. There was a significant correlation 
(r=0.595, p=0.011) between the expression of MHC class-ll molecules on 
the surface of stimulated monocytes and the levels of IFN-gamma present in 
the activated supernatants. However there was no correlation between 
levels of MHC II expression on the monocytes and % generated tumour 
cytotoxicity The concentration of TNF-alpha the monocytes secreted was 
directly proportional to the level of generated cytotoxicity, therefore the most 
probable mechanism for tumour cell death. The % expression/intensity of the 
adhesion molecules LFA-1 and Mac-1 did not appear to change with the 
addition of the LAK supernatants.
Therefore, in summary, the 200U/ml dose of IL-2 stimulated PBMC to 
secrete IFN-gamma and IL-1 in their highest concentrations. These 
cytokines then caused the upregulation of MHC II molecules on the surface 
of peripheral blood monocytes, thus activating them. The activated 
monocytes secreted a high concentration of TNF-alpha which correlated to 
the levels of generated monocyte mediated tumour cytotoxicity, thus a 
possible effector mechanism was observed (See Figure 8).
The positive results obtained here must be weighed up against 
negative side-effects of IL-2 therapy, which may have a dramatic effect in 
vivo. Firstly, the administration of IL-2 causes capillaries to leak 
(Ettinghausen et al. 1988 (75)); this can have a dramatic effect on the body 
as a whole. This occurrence has been postulated to enable phagocytes to 
enter the tissue easily from capillaries, so any administration of IL-2 must be 
at the tumour site thereby having a local effect while diluting systemic 
toxicity. TNF-alpha not only has a well documented anti-tumour response in 
animals but also has been shown to promote tumour cell adhesion to the 
peritoneum and so enhance the establishment of multiple tumours below the 
peritoneal surface in tumour-bearing mice (76). Finally Parry et al. 1992 (77) 
reported that monocytes secrete factors which cause the proliferation of 
tumour cells, therefore, in any supernatant added, these factors would have 
to be negated. The model proposed here would need to be examined in vivo 
to examine this trend and ascertain if the positive effects outweigh the 
negative side-effects. The main problem with working with the cytokine 
network and the immune system is the various cascades which are set into 
motion by the changing of one variable. Using the correct dose of IL-2 
produces a cascade effect which ends in monocyte mediated cytotoxicity
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invitro but as with most results observed when manipulating the immune 
system the knock on effects in vivo can produce a wide range of the is a 
whole new ball game.
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FIGURE 8
A schematic representation of the events thought to be 
involved in the optimal stimulation by LAK supernatants, 
upon human monocyte tumour ceil cyto toxic ity
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5.2 Recent Literature review and Future Work
Kuramitsu et al. discovered that TGF-beta could be used as a 
chemoattractant for LAK cells in vitro (79). If this could be used in humans, 
LAK cells could be targeted to the sight of tumours by either direct 
exogenous injection of the cytokine at the tumour site or by the use of 
antibodies attached to slow release liposomes containing the cytokine which 
have been engineered to target, tumour specific antigens. Heaton and 
Grimm used an antibody (HTac) which had specificity against the high/low 
affinity IL-2 receptor (IL-2R) of human PBMC. They found that when added to 
IL-2 activated PBMC there was a dramatic reduction in proliferation and 
secretion of the cytokines IFN-yand TNF-a but no decrease in LAK activity. 
Another antibody (HMik) which was specific against the intermediate affinity 
IL-2 receptor (IL-2R) when used in a similar experiment, inhibited LAK 
activation and proliferation but had little effect on cytokine secretion (80). 
Therefore this data suggests LAK activity is mediated through the 
intermediate affinity IL-2R and cytokine secretion is mediated through the 
high low affinity complex, interaction between IL-2 and both of these 
complexes is required for the induction and maintenance of proliferative 
effects by human PBMC’s.
Kirsch et al. 1994 demonstrated that IFN-gamma and TNF-alpha 
when used together activated human monocytes to kill tumour cells in a 
heightened way to either of the cytokines alone (81) . To examine If LAK 
activity could be heightened above that seen with IL-2 alone, IL-6, IL-7, IFN- 
alpha, and IFN-gamma were used in conjunction with optimal and sub- 
optimal doses of IL-2. Exposure with IL-6 and IL-7 with sub-optimal doses of 
IL-2 led to increased proliferation after stimulation this increase was not 
observed in cytotoxicity. Thus these cytokines could be examined in my 
experiments to produce heightened cytokine concentrations in the 
supernatants (82) . Fujiwara and Grimm in 1992 reported that a combination 
of IL-1 and IL-2 increased TNF-alpha synthesis in PBMC than stimulation 
with IL-2 alone(83). Tumour cell lines have been transduced using 
retroviruses in vitro TNF-alpha and IFN-gamma (84). If this transduction 
could be brought occur in vivo the tumour itself could stimulate the immune 
system to destroy itself.
One of the most commonly abnormalities able to be detected in 
human cancer is mutation of the p53 tumour suppresser gene. The function 
of the p53 gene is the induction of apoptotic cell death. Loss of p53 causes 
an increased resistance to radio- and chemo-therapeutic agents (85).
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Moreover mutation of the tumour suppresser genes is thought to contribute 
to tumour cell growth by activating proteins which normally limit cell 
proliferation. (86). A recently cloned TNF family member (TNF-related 
apoptosis -inducing ligand (TRAIL))has been identified that induces 
apoptosis in a wide variety of cell lines of diverse origin. (87). This cytokine 
could be examined in my experiments to see if this was the mechanism 
through which the monocytes were killing the tumour cells.
To verify the effect observed from the results pure cytokines could be 
added to stimulate monocytes to reproduce the levels of cytotoxicity seen 
with that produced with the LAK supernatants. Cytokine synergy could also 
be examined by using antibody blocking against the relevant cytokines of 
the supernatants.
The anti-CD3 supernatants did not increase monocyte tumour 
cytotoxicity very much but contained IL-I. Thus this may be circumstantial 
evidence that other stimulatory factors are present in the IL-2 produced LAK 
supernatants. Such proteins could be other cytokines e.g. GM-CSF or IL-6, 
these could be examined in a similar manner to TNF-alpha, IFN-gamma and 
IL-I to quantify any role in which they may contribute to monocyte tumour 
cytotoxicity (stimulated by LAK supernatants).
Also the use of LAK supernatants could be evaluated in vivo by using 
a SCID or nude mouse model. Here the mice could be reconstituted with 
human PBMC and/or monocytes. IL-2 at the correct concentrations could be 
administered and the effect of LAK secretions upon monocyte mediated 
tumour cell killing could be examined. From the work carried out by Kluppen 
et al. 1992 (88) the site of administration would be local to the tumour. The 
extent of particular LAK cell secretions could be examined not only upon 
monocytes but also PBMC and monocytes thus the extent of monocyte and T 
cell cytotoxicity could simultaneously be examined.
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